2024
Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration
Szmulewicz A, Martínez-Alés G, Logan R, Ferrara M, Kelly C, Fredrikson D, Gago J, Conderino S, Díaz-Caneja C, Galvañ J, Thorpe L, Srihari V, Yatham L, Sarpal D, Shinn A, Arango C, Öngür D, Hernán M, Collaboration O. Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration. American Journal Of Epidemiology 2024, 193: 1081-1087. PMID: 38576166, DOI: 10.1093/aje/kwae029.Peer-Reviewed Original ResearchFirst-episode psychosisFirst-generation agentsAntipsychotic therapyAntipsychotic drugsPsychosis onsetPsychotic disordersEpisode psychosisAripiprazolePaliperidoneRisk of hospitalizationPsychosisTarget trialsRisperidoneOlanzapineFirst-line therapyTreatment discontinuationEUFESTObservational cohortAntipsychoticsQuetiapineRandomized trialsPrimary outcomeAbsolute riskRisk differenceClinical questions
2018
Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression
Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig TJ, Nordentoft M, Srihari VH, Guloksuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn D, Severe JB, Kane JM. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry 2018, 75: 555-565. PMID: 29800949, PMCID: PMC6137532, DOI: 10.1001/jamapsychiatry.2018.0623.Peer-Reviewed Original ResearchConceptsEarly phase psychosisEarly intervention servicesCause treatment discontinuationSchizophrenia spectrum disordersSymptom severityTreatment discontinuationPsychiatric hospitalizationSystematic reviewIntervention servicesMonths of treatmentEnd of treatmentFirst-episode psychosisTotal symptom severitySystematic literature searchMeta-regression analysisPositive symptom severityCoprimary outcomesPrespecified subgroupsLanguage restrictionsNegative symptom severityClinical trialsTreatment periodMAIN OUTCOMESpectrum disorderPRISMA guidelines